CEACAM5 and metastatic neoplasm: As expected, the most established PDAC biomarkers CEA, CA 19–9 and CYFRA 21–1 correlated with poorer prognosis in metastatic disease (HR 1.002, 95% CI 1.0004–1.004, p = 0.019, HR 1.00001, 95% CI 1.00001–1.00002, p = 0.0001 and HR 1.004, 95% CI 1.001–1.006, p = 0.003, respectively, Table 2).